Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: A multicenter, randomized clinical trial
Open accessAbstract
Background Several studies have demonstrated that spironolactone has an anti-albuminuric property in diabetic nephropathy. As an adverse event, spironolactone often induces the elevation of creatinine levels with hypotension and hyperkalemia. Therefore, we aimed to evaluate the efficacy and safety of spironolactone in Japanese patients with type 2 diabetes treated with either angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.Methods Fifty-two Japanese patients with diabetic nephropathy and albuminuria (100 mg/gCr-2000 mg/gCr) treated with renin-angiotensin system (RAS) blockade were enrolled in a prospective, randomized, open-label study. The patients were subjected to add-on treatment with spironolactone 25 mg once daily and compared with matched controls for 8 weeks. The primary outcome was a reduction in the rate of albuminuria at 8 weeks compared with the baseline value. This study was registered with UMIN Clinical Trials Registry (000008016).Results Albuminuria was reduced by 33 % (95 % confidence interval: 22-54; P = 0.0002) at 8 weeks with spironolactone. In the spironolactone group, blood pressure tended to lower and the estimated glomerular filtration rate (eGFR) was significantly decreased compared to those in the control group. When adjusted by systolic blood pressure and eGFR, spironolactone treatment still showed a significant effect on albuminuria reduction in a linear mixed model (coefficient ± standard error; 514.4 ± 137.6 mg/gCr, P < 0.0005). No patient was excluded from the study because of hyperkalemia.Conclusions Spironolactone reduced albuminuria along with conventional RAS inhibitors in patients with diabetic nephropathy. Our study suggests that spironolactone exerts anti-albuminuric effects independent of systemic hemodynamic alterations.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In type 2 diabetes, blood pressure control reduces the risk of onset and progression of microvascular and macrovascular disease, including diabetic kidney disease and retinopathy.
“During the course of T2D, an early primary goal is BP control to reduce risk of onset and progression of micro- and macrovascular disease, to include DKD and retinopathy.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [191]
The Introduction (page unavailable) says intensive glucose and blood-pressure control reduces proteinuria, slows renal dysfunction, and protects against microvascular complications; it identifies nephropathy and retinopathy as microvascular diseases. It does not say that blood-pressure control reduces the onset or progression of macrovascular disease, or establish that blood-pressure control alone accounts for all the stated benefits. (LLM, conf=0.85)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214 · see citing works
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · see citing works
Revised Equations for Estimated GFR From Serum Creatinine in Japan
Matsuo, S., Imai, E., Horio, M., Yasuda, Y., Tomita, K., Nitta, K., Yamagata, K., Tomino, Y., Yokoyama, H., & Hishida, A. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.12.034 · Cited by 6,439 · see citing works
Self-citationGlobal and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883 · see citing works
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F. M., Remme, W. J., Cody, R. J., Castaigne, A., Pérez, A. J. P., Palensky, J., & Wittes, J. T. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927 · see citing works
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873 · see citing works
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Parving, H., Lehnert, H., Brøchner‐Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · PubMed · Cited by 2,527 · see citing works
Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy
Sato, A., Hayashi, K., Naruse, M., & Saruta, T. (2003) · Hypertension · doi:10.1161/01.hyp.0000044937.95080.e9 · Cited by 466 · cited 1× · see citing works
“Since 20–50 % of hypertensive patients on long-term RAS blockers use were reported to fall into ‘‘aldosterone breakthrough’’ and would benefit from the addition of spironolactone [28, 29], for such patients the use of spironolactone should be recommended.”
Shibata, S., Nagase, M., Yoshida, S., Kawarazaki, W., Kurihara, H., Tanaka, H., Miyoshi, J., Takai, Y., & Fujita, T. (2008) · Nature Medicine · doi:10.1038/nm.1879 · Cited by 463 · see citing works
An Overview of Regular Dialysis Treatment in Japan (As of 31 December 2013)
Masakane, I., Nakai, S., Ogata, S., Kimata, N., Hanafusa, N., Hamano, T., Wakai, K., Wada, A., & Nitta, K. (2015) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12378 · Cited by 428 · see citing works
Mehdi, U. F., Adams-Huet, B., Raskin, P., Vega, G. L., & Toto, R. D. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009070737 · Cited by 388 · see citing works
Bianchi, S., Bigazzi, R., & Campese, V. M. (2006) · Kidney International · doi:10.1038/sj.ki.5001854 · Cited by 337 · see citing works
GFR Estimation Using Standardized Serum Cystatin C in Japan
Horio, M., Imai, E., Yasuda, Y., Watanabe, T., & Matsuo, S. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.007 · Cited by 325 · see citing works
Self-citationRossing, K., Schjoedt, K. J., Smidt, U., Boomsma, F., & Parving, H. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2106 · Cited by 297 · see citing works
Wolf, G., & Ritz, E. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00145.x · Cited by 284 · see citing works
Nathan, D. M., Bayless, M., Cleary, P. A., GENUTH, S. M., Gubitosi‐Klug, R., Lachin, J. M., Lorenzi, G. M., & Zinman, B. (2013) · Diabetes · doi:10.2337/db13-1093 · Cited by 272 · see citing works
Chrysostomou, A., & Becker, G. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200109203451215 · Cited by 264 · see citing works
Bomback, A. S., Kshirsagar, A. V., Amamoo, M. A., & Klemmer, P. J. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.10.040 · Cited by 261 · see citing works
Beneficial impact of spironolactone in diabetic nephropathy
Schjoedt, K. J., Rossing, K., Juhl, T. R., Boomsma, F., Rossing, P. R., Tarnow, L., & Parving, H. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00756.x · Cited by 237 · see citing works
Makino, H., Haneda, M., Babazono, T., Moriya, T., Ito, S., Iwamoto, Y., Kawamori, R., Takeuchi, M., Katayama, S., & for the INNOVATION Study Group (2007) · Diabetes Care · doi:10.2337/dc06-1998 · Cited by 230 · see citing works
Self-citationvan den Meiracker, A. H., Baggen, R. G. A., Pauli, S., Lindemans, A. D., Vulto, A. G., Poldermans, D., & Boomsma, F. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000249708.44016.5c · Cited by 187 · see citing works
Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats
Fujisawa, G., Okada, K., Muto, S., Fujita, N., Itabashi, N., Kusano, E., & Ishibashi, S. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00913.x · Cited by 179 · see citing works
Microvascular disease: what does the UKPDS tell us about diabetic nephropathy?
Bilous, R. W. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02496.x · Cited by 176 · see citing works
The renal tubulointerstitium in diabetes mellitus
Ziyadeh, F. N., & Goldfarb, S. (1991) · Kidney International · doi:10.1038/ki.1991.57 · Cited by 167 · see citing works
Araki, S., Haneda, M., Koya, D., Hidaka, H., Sugimoto, T., Isono, M., Isshiki, K., Chin‒Kanasaki, M., Uzu, T., & Kashiwagi, A. (2007) · Diabetes · doi:10.2337/db06-1646 · Cited by 162 · see citing works
Self-citationKobori, H., Ozawa, Y., Suzaki, Y., & Nishiyama, A. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004080676 · Cited by 155 · see citing works
Self-citationOverview of Regular Dialysis Treatment in Japan (as of 31 December 2009)
Nakai, S., Iseki, K., Itami, N., Ogata, S., Kazama, J. J., Kimata, N., Shigematsu, T., Shinoda, T., Shoji, T., Suzuki, K., et al. (2012) · Therapeutic Apheresis and Dialysis · doi:10.1111/j.1744-9987.2011.01050.x · Cited by 100 · see citing works
Furumatsu, Y., Nagasawa, Y., Tomida, K., Mikami, S., Kaneko, T., Okada, N., Tsubakihara, Y., Imai, E., & Shoji, T. (2008) · Hypertension Research · doi:10.1291/hypres.31.59 · Cited by 97 · see citing works
Self-citationMavrakanas, T. A., Gariani, K., & Martin, P. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.11.007 · Cited by 82 · see citing works
Makino, H., Haneda, M., Babazono, T., Moriya, T., Ito, S., Iwamoto, Y., Kawamori, R., Takeuchi, M., & Katayama, S. (2008) · Hypertension Research · doi:10.1291/hypres.31.657 · Cited by 74 · see citing works
Self-citationKramer, A., van der Meulen, E. F., Hamming, I., van Goor, H., & Navis, G. (2007) · Kidney International · doi:10.1038/sj.ki.5002075 · Cited by 61 · see citing works
Esteghamati, A., Noshad, S., Jarrah, S., Mousavizadeh, M., Khoee, S. H., & Nakhjavani, M. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft281 · Cited by 60 · see citing works
Yoneda, T., Takeda, Y., Usukura, M., Oda, N., Takata, H., Yamamoto, Y., Karashima, S., & Yamagishi, M. (2007) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2007.09.001 · Cited by 55 · see citing works
Morales, E., Millet, V. G., Rojas-Rivera, J. E., Huerta, A., Gutiérrez, E., Gutiérrez-Solís, E., Egido, J., & Praga, M. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs429 · Cited by 53 · see citing works
Ojeda‐Cervantes, M., Barrera‐Chimal, J., Alberú, J., Pérez‐Villalva, R., Morales-Buenrostro, L. E., & Bobadilla, N. A. (2013) · American Journal of Nephrology · doi:10.1159/000350539 · Cited by 50 · see citing works
Nishiyama, A., Kobori, H., Konishi, Y., Morikawa, T., Maeda, I., Okumura, M., Kishida, M., Hamada, M., Nagai, Y., Nakagawa, T., et al. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.158113 · Cited by 48 · see citing works
Self-citationChen, H., Sun, F., Zhong, X., Shao, Y., Yoshimura, A., & Liu, Y. (2013) · Kidney & Blood Pressure Research · doi:10.1159/000355736 · Cited by 46 · see citing works
Konishi, Y., Nishiyama, A., Morikawa, T., Kitabayashi, C., Shibata, M., Hamada, M., Kishida, M., Hitomi, H., Kiyomoto, H., Miyashita, T., et al. (2011) · Hypertension · doi:10.1161/hypertensionaha.110.166843 · Cited by 42 · see citing works
Self-citationWoo, K., Choi, J.-L., Kim, B., Kim, J.-E., An, W.-S., & Han, J. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.4.307 · Cited by 42 · see citing works
Predictors of diabetic end‐stage renal disease in Japan
Iseki, K. (2005) · Nephrology · doi:10.1111/j.1440-1797.2005.00447.x · Cited by 22 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507 · see citing works
Chung, E. Y., Ruospo, M., Natale, P., Bolignano, D., Navaneethan, S. D., Palmer, S. C., & Strippoli, G. F. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007004.pub4 · Cited by 157 · see citing works
Blood pressure control in type 2 diabetic patients
Grossman, A., & Grossman, E. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0485-3 · Cited by 134 · see citing works
Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease
Alexandrou, M. E., Papagianni, A. A., Τσάπας, Α., Loutradis, C., Boutou, A., Piperidou, A., Papadopoulou, D., Ruilope, L. M., Bakris, G. L., & Sarafidis, P. A. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002187 · Cited by 102 · see citing works
Effects of RAAS Inhibitors in Patients with Kidney Disease
Zhang, F., Liu, H., Liu, D., Liu, Y., Li, H., Tan, X., Liu, F., Peng, Y., & Zhang, H. (2017) · Current Hypertension Reports · doi:10.1007/s11906-017-0771-9 · Cited by 98 · see citing works
Improvements in the Management of Diabetic Nephropathy
Dounousi, E. C., Duni, Α., Leivaditis, K., Vaios, V., Eleftheriadis, T., & Liakopoulos, V. (2015) · The Review of Diabetic Studies · doi:10.1900/rds.2015.12.119 · Cited by 82 · see citing works
Twenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy
Johnson, S. A., & Spurney, R. F. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00266.2015 · Cited by 75 · see citing works
Ortíz, A., Ferro, C. J., Balafa, O. C., Burnier, M., Ekart, R., Halimi, J., Kreutz, R. H., Mark, P. B., Persu, A., Rossignol, P., et al. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab167 · Cited by 64 · see citing works
Role of mineralocorticoid receptor antagonists in kidney diseases
PATEL, V. G., Joharapurkar, A. A., & Jain, M. R. (2020) · Drug Development Research · doi:10.1002/ddr.21760 · Cited by 61 · see citing works
Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy
Sun, L., Sun, Y., Shan, J., & Jiang, G. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12629 · Cited by 55 · see citing works
Glucose 6-phosphate dehydrogenase and the kidney
Spencer, N. Y., & Stanton, R. C. (2016) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000294 · Cited by 54 · see citing works
Itoh, H., Ito, S., Rakugi, H., Okuda, Y., & Nishioka, S. (2019) · Hypertension Research · doi:10.1038/s41440-019-0270-2 · Cited by 54 · see citing works
Feng, Y., Huang, R., Kavanagh, J., Li, L., Zeng, X., Li, Y., & Fu, P. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-00321-5 · Cited by 53 · see citing works
Guo, Q., Zhong, W., Duan, A., Sun, G., Cui, W., Zhuang, X., & Liu, L. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.022 · Cited by 49 · see citing works
Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes
Dong, D. F., Fan, T., Ji, Y., Yu, J., Wu, S., & Zhang, L. (2019) · International Urology and Nephrology · doi:10.1007/s11255-019-02074-9 · Cited by 48 · see citing works
Sarafidis, P. A., Iatridi, F., Ferro, C. J., Alexandrou, M. E., Fernández‐Fernández, B., Kanbay, M., Mallamaci, F., Nistor, I., Rossignol, P., Wanner, C., et al. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad139 · Cited by 47 · see citing works
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
Kawanami, D., Takashi, Y., Muta, Y., Oda, N., Nagata, D., Takahashi, H., & Tanabe, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.754239 · Cited by 42 · see citing works
Whitlock, R. H., Leon, S. J., Manacsa, H., Askin, N., Rigatto, C., Fatoba, S., Farag, Y. M. K., & Tangri, N. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad101 · Cited by 43 · see citing works
Bhuiyan, A. S., Rafiq, K., Kobara, H., Masaki, T., Nakano, D., & Nishiyama, A. (2019) · Hypertension Research · doi:10.1038/s41440-019-0211-0 · Cited by 40 · see citing works
Self-citationChen, Y., Liu, P., Chen, X., Li, Y., Zhang, F., & Wang, Y. (2018) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2018.01.017 · Cited by 35 · see citing works
Zuo, C., & Xu, G. (2019) · International Journal of Clinical Practice · doi:10.1111/ijcp.13413 · Cited by 35 · see citing works
Hyperkalemia and Acute Kidney Injury with Spironolactone Use Among Patients with Heart Failure
Secora, A. M., Shin, J., Qiao, Y., Alexander, G. C., Chang, A. R., Inker, L., Coresh, J., & Grams, M. E. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.03.035 · Cited by 33 · see citing works
Mineralocorticoid Receptor Antagonists—Use in Chronic Kidney Disease
Baran, W., Krzemińska, J., Szlagor, M., Wronka, M., Młynarska, E., Franczyk, B., & Rysz, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189995 · Cited by 32 · see citing works
Sarafidis, P. A., Memmos, E., Alexandrou, M. E., & Papagianni, A. A. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190306162658 · Cited by 30 · see citing works
Mokadem, M. E., Hady, Y. A. A. E., & Aziz, A. (2020) · Cardiorenal Medicine · doi:10.1159/000508670 · Cited by 29 · see citing works
Mineralocorticoid receptor antagonists in patients with chronic kidney disease
Cosimato, C., Agoritsas, T., & Mavrakanas, T. A. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107701 · Cited by 29 · see citing works
Wilcox, C. S., & Pitt, B. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000960 · Cited by 25 · see citing works
Urinary peptidomics in kidney disease and drug research
Krochmal, M., Schanstra, J. P., & Mischak, H. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1418320 · Cited by 24 · see citing works
Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy?
Majewski, C., & Bakris, G. L. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0713-y · Cited by 23 · see citing works
Efficacy and Safety of Low-dose Spironolactone for Chronic Kidney Disease in Type 2 Diabetes
Oiwa, A., Hiwatashi, D., Takeda, T., Miyamoto, T., Kawata, I., Koinuma, M., Yamazaki, M., & Komatsu, M. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad144 · Cited by 22 · see citing works
The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy
Goenka, L., Padmanaban, R., & George, M. (2018) · Current Clinical Pharmacology · doi:10.2174/1574884713666181116100946 · Cited by 19 · see citing works
Wander, G. S., Panda, J. K., Pal, J., Mathur, G., Sahay, R. K., TIWASKAR, M. H., Chatterjee, N., Chakrabarty, S., Singh, D. P., Murthy, L. S., et al. (2024) · Journal of the Association of Physicians of India · doi:10.59556/japi.72.0620 · Cited by 16 · see citing works
Zapata, L. V., Carhart, B., Horn, J. R., Hansten, P. D., Subbian, V., Gephart, S. M., Tan, M. S., Romero, A. V., & Malone, D. C. (2021) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxab215 · Cited by 14 · see citing works
Morita, R., Tsukamoto, S., Obata, S., Yamada, T., Uneda, K., Uehara, T., Rehman, M. E., Azushima, K., Wakui, H., & Tamura, K. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14976 · Cited by 14 · see citing works
Kato, S., Ando, M., Mizukoshi, T., Nagata, T., Katsuno, T., Kosugi, T., Tsuboi, N., & Maruyama, S. (2016) · Europe PMC (PubMed Central) · doi:10.18999/nagjms.78.2.135 · Cited by 12 · see citing works
Self-citationRole of Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
Alexandrou, M. E., Theodorakopoulou, M. P., & Sarafidis, P. A. (2022) · Kidney and Dialysis · doi:10.3390/kidneydial2020019 · Cited by 12 · see citing works
Li, Y., Xie, N., & Liang, M. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/1925243 · Cited by 11 · see citing works
Renoprotective Effects of Mineralocorticoid Receptor Antagonists Against Diabetic Kidney Disease
Bayne, S., LeFevre, J., Olstinske, K., Ravindran, S., & Munusamy, S. (2023) · Advanced Biology · doi:10.1002/adbi.202300496 · Cited by 8 · see citing works
Ding, K., Li, Z., Lu, Y., & Sun, L. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.05.038 · Cited by 8 · see citing works
Minutolo, R., Borrelli, S., Ambrosini, A., Amoroso, L., Aucella, F., Batini, V., Battaglia, Y., Bregoli, L., Cantaluppi, V., Cianciolo, G., et al. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae396 · Cited by 7 · see citing works
Yamao, Y., Ota, M., & Kanasaki, K. (2025) · Diabetology International · doi:10.1007/s13340-025-00839-5 · Cited by 6 · see citing works
Self-citationMineralocorticoid receptor blockage in kidney transplantation: too much of a good thing or not?
Afşar, B., Afşar, R. E., Çalışkan, Y., & Lentine, K. L. (2024) · International Urology and Nephrology · doi:10.1007/s11255-024-04256-6 · Cited by 6 · see citing works
Dibo, P., Mareddy, N. S. R., Kojima, G. S. A., Ershed, M., Obi, O. S., Razaq, S., & Kumar, V. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04161-9 · Cited by 4 · see citing works
Mitsuboshi, S., Morizumi, M., Imai, S., Hori, S., & Kotake, K. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.4618 · Cited by 4 · see citing works
Relationship between serum Dickkopf-1 and albuminuria in patients with type 2 diabetes
Hou, N., Kan, C., Huang, N., Liu, Y., Mao, E.-W., Ma, Y.-T., Han, F., Hong-xi, S., & Sun, X. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i1.47 · Cited by 4 · see citing works
Amini, M., Dalil, D., Yaghoubi, F., Valizadeh, Z., Tavakoli, F., & Koohpayezadeh, Z. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70058 · Cited by 3 · see citing works
Donderski, R. Ł., & Manitius, J. (2019) · Arterial Hypertension · doi:10.5603/ah.a2018.0016 · Cited by 2 · see citing works
Verdalles, Ú., Goicoechea, M., de Vinuesa, S. G., Torres, E., Hernández, A., Verde, E., de José, A. P., & Luño, J. (2019) · Nefrología · doi:10.1016/j.nefro.2019.04.012 · Cited by 2 · see citing works
Athyros, V. G., Sachinidis, A. G., Zografou, I., Simoulidou, E., Piperidou, A., Stavropoulos, N., & Karagiannis, A. I. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190306162339 · Cited by 1 · see citing works
Watanabe, T., Maeda, K., Kato, N., Seko, H., Sugimura, M., Sato, Y., Ryuge, A., Kato, S., Kadomatsu, K., Maruyama, S., et al. (2023) · Nephrology · doi:10.1111/nep.14227 · Cited by 1 · see citing works
Self-citationProteomanalyse: Neue Wege zur verbesserten Behandlung der diabetischen Nephropathie
Drube, J., Zürbig, P., Beige, J., Mischak, H., & Jankowski, J. (2017) · Diabetologie und Stoffwechsel · doi:10.1055/s-0043-106192 · Cited by 1 · see citing works
Shah, N., Perkovic, V., & Kotwal, S. S. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2108402 · Cited by 1 · see citing works
Lindner, T. H. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0114-5
Aldosterone and the mineralocorticoid receptor in insulin resistance and diabetes
Toloza, F. J. K., & Mendivil, C. O. (2017) · Alad · doi:10.24875/alad.m17000001
Giri, R., Naresh, A., Kushwaha, J. S., Kumar, B. N., Verma, R. K., & Khan, M. I. (2019) · International Journal of Advances in Medicine · doi:10.18203/2349-3933.ijam20190120
Verdalles, Ú., Goicoechea, M., de Vinuesa, S. G., Torres, E., Hernández, A., Verde, E., de José, A. P., & Luño, J. (2020) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2019.04.004
Kanasaki, K. (2022) · Hypertension Research · doi:10.1038/s41440-022-01107-8
Self-citationResearch Progress in Treatment of Diabetic Proteinuria
李, 欢. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2022.132173
Therapieoptionen bei diabetischer Nephropathie
Morgenroth, R., Mertens, P. R., Herzog, C. A., & Scurt, F. G. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01003-w
Lin, W., Huang, T.-S., Chang, H.-H., Chao, J.-Y., Chang, Y.-H., Yang, C., Ou, H., & Lin, W. (2026) · Clinical and Translational Science · doi:10.1111/cts.70509
Mineralocorticoid Receptor Antagonists for Renoprotection and Cardioprotection in CKD
Iatridi, F., & Theodorakopoulou, M. P. (2026) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-032-29564-4_16
Dose-Specific Network Meta-Analysis of Mineralocorticoid Receptor Antagonists in CKD
Korucu, B., Colak, A., Mustafa, R., Earley, A., & Wheeler, D. C. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.107084
- Authors
- Kato, S., Maruyama, S., Makino, H., Wada, J., Ogawa, D., Uzu, T., Araki, H., Koya, D., Kanasaki, K., Oiso, Y., Goto, M., Nishiyama, A., Kobori, H., Imai, E., Ando, M., & Matsuo, S.
- Affiliations
- Nagoya University (JP)
- Okayama University (JP)
- Shiga University of Medical Science (JP)
- Kanazawa Medical University (JP)
- Kagawa University (JP)
- Nagoya University Hospital (JP)
- Corresponding author
- Kato, Sawako
- ORCID
- Venue
- Clinical and Experimental Nephrology
- Published
- 2015-03-21
- Volume
- 19
- Issue
- 6
- Pages
- 1098-1106
- ISSN
- 1342-1751 (ISSN-L)
- 1437-7799
- PMC
- PMC4577308
- OpenAlex
- W2067121693
- Cited by
- 61
- References
- 40
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 4 · 2023: 9 · 2022: 4 · 2021: 5 · 2020: 7 · 2019: 13 · 2018: 2 · 2017: 6 · 2016: 4 · 2015: 2
- FWCI
- 4.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Clinical and Experimental Nephrology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Japan Society for the Promotion of Science (25460896)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK072408)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- spironolactone, diabetic nephropathy, albuminuria, type 2 diabetes, renin-angiotensin system blockade, ACE inhibitors, angiotensin receptor blockers, adjunctive therapy, estimated glomerular filtration rate, blood pressure, hyperkalemia, Japanese patients
- MeSH terms
- Adult, Aged, Albuminuria, Aldosterone, Mineralocorticoid Receptor Antagonists, Blood Pressure, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Female, Glomerular Filtration Rate, Humans, Male, Middle Aged, Prospective Studies, Spironolactone, Treatment Outcome, Asian People
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
